Literature DB >> 26094142

IL-37b suppresses T cell priming by modulating dendritic cell maturation and cytokine production via dampening ERK/NF-κB/S6K signalings.

Wantong Wu1, Weiqiang Wang2, Yun Wang3, Wenwen Li2, Gang Yu4, Zhonglong Li4, Chunmin Fang4, Yue Shen4, Zhina Sun4, Ling Han4, Juan Yu4, Lijun Fang4, Song Chen4, Kui Dong2, Zhongchao Han4, Hanzhi Liu4, Yuechen Luo5, Xiaoming Feng5.   

Abstract

Interleukin 37b (IL-37b) plays a key role in suppressing immune responses, partially by modulating the function of dendritic cells (DCs). However, the precise mechanisms are still largely unknown. Here, we investigated the effects of IL-37b on DC maturation and T cell responses induced by DCs, and explored the involved signaling pathways. It was found that IL-37b down-regulated the expressions of co-stimulatory molecules CD80 and CD86 on DCs in vitro. At the same time, the expressions of pro-inflammatory cytokines, such as TNF-α and IL-6, were suppressed, while the expression of the T cell inhibitory cytokine TGF-β was increased in IL-37b-treated DCs. In addition, the activation effect of DCs on T cells was impaired by IL-37b. We further revealed that extracellular single-regulated kinase (ERK), nuclear factor-κB (NF-κB), and mTOR-S6K signaling pathways were involved in the inhibition of DCs induced by IL-37b. This was confirmed by the similarly suppressive effect of chemical inhibitors against NF-κB, ERK, and S6K on the expressions of IL-6 and TNF-α in DCs. In conclusion, these results demonstrated that IL-37b suppressed DC maturation and immunostimulatory capacity in T cell priming by involving in ERK, NF-κB, and S6K-based inhibitory signaling pathways.
© The Author 2015. Published by ABBS Editorial Office in association with Oxford University Press on behalf of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

Entities:  

Keywords:  IL-37b; cytokines; dendritic cells

Mesh:

Substances:

Year:  2015        PMID: 26094142     DOI: 10.1093/abbs/gmv058

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  9 in total

Review 1.  Biology of interleukin-37 and its role in autoimmune diseases (Review).

Authors:  Huiqiong Zeng; Kaixia Zhou; Zhizhong Ye
Journal:  Exp Ther Med       Date:  2022-06-07       Impact factor: 2.751

2.  Cynomolgus macaque IL37 polymorphism and control of SIV infection.

Authors:  Takashi Shiina; Shingo Suzuki; Nicolas Congy-Jolivet; Alice Aarnink; Henri-Jean Garchon; Nathalie Dereuddre-Bosquet; Bruno Vaslin; Nicolas Tchitchek; Delphine Desjardins; Brigitte Autran; Olivier Lambotte; Ioannis Theodorou; Roger Le Grand; Antoine Blancher
Journal:  Sci Rep       Date:  2019-05-28       Impact factor: 4.379

Review 3.  Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.

Authors:  Xi Chen; Xiaohui Pan; Wenxin Zhang; Hongjie Guo; Shuyuan Cheng; Qiaojun He; Bo Yang; Ling Ding
Journal:  Acta Pharm Sin B       Date:  2019-09-25       Impact factor: 11.413

Review 4.  Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy.

Authors:  Yu Yuan; Abdalla Adam; Chen Zhao; Honglei Chen
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639

Review 5.  Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors.

Authors:  Sarah E Fenton; Jeffrey A Sosman; Sunandana Chandra
Journal:  Cancer Drug Resist       Date:  2019-09-19

6.  Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma.

Authors:  Teresa Amaral; Olivia Seeber; Edgar Mersi; Stephanie Sanchez; Ioannis Thomas; Andreas Meiwes; Andrea Forschner; Ulrike Leiter; Thomas Eigentler; Ulrike Keim; Claus Garbe
Journal:  Cancers (Basel)       Date:  2020-04-22       Impact factor: 6.639

7.  GWAS for Interleukin-1β levels in gingival crevicular fluid identifies IL37 variants in periodontal inflammation.

Authors:  Steven Offenbacher; Yizu Jiao; Steven J Kim; Julie Marchesan; Kevin L Moss; Li Jing; Kimon Divaris; Sompop Bencharit; Cary S Agler; Thiago Morelli; Shaoping Zhang; Lu Sun; William T Seaman; Dale Cowley; Silvana P Barros; James D Beck; Matthias Munz; Arne S Schaefer; Kari E North
Journal:  Nat Commun       Date:  2018-09-11       Impact factor: 14.919

8.  IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer.

Authors:  Tiansuo Zhao; Fanjie Jin; Di Xiao; Hongwei Wang; Chongbiao Huang; Xiuchao Wang; Song Gao; Jing Liu; Shengyu Yang; Jihui Hao
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

9.  Novel therapies targeting hypoxia mechanism to treat pancreatic cancer.

Authors:  Wenhao Luo; Jiangdong Qiu; Lianfang Zheng; Taiping Zhang
Journal:  Chin J Cancer Res       Date:  2021-04-30       Impact factor: 5.087

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.